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Summary
Interventions that extend lifespan in mice can show substantial
sexual dimorphism. Here, we show that male-specific lifespan
extension with two pharmacological treatments, acarbose (ACA)
and 17-a estradiol (17aE2), is associated, in males only, with
increased insulin sensitivity and improved glucose tolerance.
Females, which show either smaller (ACA) or no lifespan exten-
sion (17aE2), do not derive these metabolic benefits from drug
treatment. We find that these male-specific metabolic improve-
ments are associated with enhanced hepatic mTORC2 signaling,
increased Akt activity, and phosphorylation of FOXO1a – changes
that might promote metabolic health and survival in males. By
manipulating sex hormone levels through gonadectomy, we
show that sex-specific changes in these metabolic pathways are
modulated, in opposite directions, by both male and female
gonadal hormones: Castrated males show fewer metabolic
responses to drug treatment than intact males, and only those
that are also observed in intact females, while ovariectomized
females show some responses similar to those seen in intact
males. Our results demonstrate that sex-specific metabolic
benefits occur concordantly with sexual dimorphism in lifespan
extension. These sex-specific effects can be influenced by the
presence of both male and female gonadal hormones, suggesting
that gonadally derived hormones from both sexes may con-
tribute to sexual dimorphism in responses to interventions that
extend mouse lifespan.
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Introduction
There is increasing recognition that lifespan-extending manipulations can
have sexually dimorphic effects on survival. Genetic impairments in several
components of the insulin-like growth factor-1 (IGF1) signaling pathway
have been shown to extend lifespan to a greater extent in female mice
than in males (Garratt et al., 2017), with reduced IGF1 signaling
sometimes generating significant lifespan extension only in females
(Holzenberger et al., 2003; Bokov et al., 2011; Svensson et al., 2011; Xu
et al., 2014). Reduced mTORC1 signaling has also been reported to
extend lifespan to a greater degree in females (Lamming et al., 2012;
Miller et al., 2014; Zhang et al., 2014; Garratt et al., 2016). By contrast,
several different pharmacological treatments, including aspirin, nordihy-
droguaiaretic acid, acarbose (ACA), Protandim, and 17-a estradiol
(17aE2), extend mouse lifespan to a greater degree in males (Harrison
et al., 2014; Strong et al., 2016). The causes for this sexual dimorphism in
lifespan extension are largely unknown (Austad & Bartke, 2015).
ACA and 17aE2 each have reproducible and robust effects on male
median and maximum lifespan, with noticeably smaller or undetectable
effects in females. ACA is a glucosidase inhibitor that slows down
carbohydrate digestion and reduces postprandial glucose spikes
(Harrison et al., 2014). Treatment with ACA can extend male lifespan
by around 20%, but leads to much smaller, although still significant, 5%
extension in females. As this drug controls excursions in blood glucose
levels, and is used to treat type II diabetes, this sexually dimorphic
lifespan response might suggest that lifespan in male mice is more
sensitive to alterations in blood glucose fluctuations than that of females.
17aE2 is a nonfeminizing steroid that has a reduced affinity for the
classical estrogen receptors (Harrison et al., 2014). Treatment of mice
with 17aE2 can extend male lifespan by 19% without any noticeable
effects in females (Strong et al., 2016). This striking sex specificity of the
lifespan effects of 17aE2 might suggest that some aspect of estrogenic
signaling, outside of the effects of classical estrogen receptor (ER)
signaling, which require strong binding affinity to ER, might be
particularly beneficial for males but not females. It has further been
suggested that 17aE2 might have particular actions in the brain, where it
can bind to a nonclassical ER receptor ER-X, which can modulate MAPK/
ERK signaling (Toran-Allerand et al., 2002, 2005). Treatment of 16-
month-old male C57BL/6 mice with 17aE2 ameliorates metabolic and
inflammatory dysfunction, suggesting that this steroid may have
metabolic benefits (Stout et al., 2016), although this report did not
include treated females as a comparison group.
A potential role of ACA and 17aE2 in improving metabolic dysfunc-
tion in males, specifically, is also consistent with sex-specific patterns of
glucose–insulin homeostasis and metabolism characteristic of mice and
humans. Males and females differ in their production of hormones
involved in the regulation of glucose metabolism, and can differ in
insulin sensitivity and glucose homeostasis (Legato, 2010). In particular,
male mice of a variety of different strains have been reported to have
lower insulin sensitivity and lower rates of glucose clearance when
compared to females (Macotela et al., 2009; Bonaventura et al., 2013;
Sadagurski et al., 2014; Shivaswamy et al., 2014). Furthermore, genetic
inhibition of several components of the insulin signaling cascade (IRS2,
mTORC2), which impair glucose homeostasis, greatly increases mortality
rates of males with noticeably smaller effects on female survival (Selman
et al., 2008; Lamming et al., 2014b). Thus, treatments that improve
glucose control might plausibly provide greater benefits to males. The
underlying causes for sex differences in glucose homeostasis are not fully
understood, but sex-specific gonadal hormone production has been
implicated. Testosterone, in some instances, can reduce insulin sensitiv-
ity, and 17-b-estradiol can provide benefits, with the latter expected to
contribute to alterations in glucose homeostasis and elevated adiposity
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after menopause (Mauvais-Jarvis, 2015). However, the effects of
testosterone and 17-b-estradiol on insulin sensitivity and glucose
metabolism can be context dependent, with each hormone reported
to have opposing effects in some instances (Geer & Shen, 2009).
In this study, we tested whether male lifespan extension with ACA
and 17aE2 is associated with benefits to males in terms of improved
glucose homeostasis, and whether these effects differ from those in
females. Because male and female lifespan and glucose homeostasis are
differentially affected by changes in mTOR signaling (Lamming et al.,
2012, 2014b), we were further interested in whether changes in mTOR
signaling may be implicated in these responses. To provide additional
insight into the hormonal underpinnings of this sex specificity, we also
examined responses to ACA and 17aE2 in castrated males and
ovariectomized (OVX) females. This endocrine manipulation allowed us
to test whether sex-specific responses to these drugs were related to the
presence of male or female gonads and associated sex-specific hormone
production.
Results
Hormones regulated similarly in both sexes
Several hormones involved in glucose control, which have previously been
reported to show sex differences in circulating concentration, were
influencedby ACAand/or 17aE2, but responseswere similar in both sexes.
Plasma adiponectin was higher in females than in males and was reduced
by ACA and 17aE2 to a similar degree in both sexes (Fig. 1A). Plasma IGF1
concentrationwas higher inmales andwas reduced by ACAand increased
by 17aE2 (Fig. 1B). Plasma leptin levelswere similar between the sexes and
were increased by 17aE2 (Fig. 1C). There was no overall effect of ACA or
17aE2 on fasting insulin levels (Fig. 1D), nor was there a significant
interaction between sex and drug treatment on fasting insulin levels for
either ACA or 17aE2 compared to control (P > 0.1 in each case). Fasting
plasma glucose levels are elevated by ACA in both sexes (Fig. 1E),
presumably a consequence of the slowed breakdown of ingested starch,
replicating findings from an earlier cohort (Harrison et al., 2014).
Sex-specific changes in insulin sensitivity with ACA and 17aE2
To test for sex-specific responses in insulin sensitivity with ACA and
17aE2 more directly, we conducted insulin tolerance tests (Fig. 1F).
Males and females showed significantly different changes in insulin
sensitivity with ACA or 17aE2 treatment, as highlighted by the
significant sex*treatment interaction terms for change in glucose after
insulin injection (Table 1). This generally reflected a slight improvement
in insulin sensitivity in males and a slight reduction in insulin sensitivity in
females, although only the reduction in insulin sensitivity for females
with ACA is significant (Table 1). Also notable was that treatment with
ACA and 17aE2 effectively suppressed the sex differences in insulin
sensitivity often observable with this test. On the control diet, males
showed less glucose responsiveness to an injection of insulin than
females, a response reported previously (Macotela et al., 2009; Bon-
aventura et al., 2013; Sadagurski et al., 2014; Shivaswamy et al., 2014).
By contrast, when males and females are treated with ACA and 17aE2,
this sex difference disappeared (Fig. 1F,G; Table 1).
Glucose tolerance
We conducted glucose tolerance tests to see whether these sex-specific
responses in insulin sensitivity lead to altered glucose tolerance with
treatment. Male mice have in some studies been found to have
decreased glucose tolerance compared to females (Stubbins et al., 2012;
Varlamov et al., 2015), which may contribute to metabolic dysfunction
in older males. As ACA leads to a consistent, sex-independent elevation
in glucose levels after fasting (Fig. 1E), likely to be due to the actions of
ACA in slowing starch breakdown, we calculated glucose excursion
following IP glucose, using glucose levels just prior to injection of a
glucose bolus as a baseline when calculating area under the curve.
Assessment of glucose excursion after either 5 or 18 months of
treatment with ACA or 17aE2 revealed that both drugs increased the
ability of males to remove administered glucose (and therefore reduce
plasma levels following injection), while having no such effect on
females (Fig. 2; Table 1). The effect of treatment on glucose excursion at
the measured time points also differed according to sex at the 30-, 60-,
and 120-minute time points, for both ACA and 17aE2 (sex by treatment
interaction: P < 0.05 at each time point for each drug). There is also a
significant effect of age in this analysis, with older animals appearing to
have improved glucose tolerance (P = 0.003 across the whole dataset),
although we are cautious of interpretation of this result as the two age
groups were tested approximately a year apart.
Sex-specific alterations in mTOR signaling after exposure to
ACA or 17aE2
Alterations in mTOR signaling have been associated with sex differences
in lifespan extension and can differentially influence glucose homeostasis
in males and females. Reduced mTORC1 signaling extends lifespan to a
greater degree in females (Lamming et al., 2012; Miller et al., 2014;
Garratt et al., 2016), while genetic inhibition of mTORC2 reduces male
lifespan without noticeably affecting females (Lamming et al., 2014b).
At least some of these sex effects have been suggested to be attributable
to the negative effects of reduced mTORC2 on glucose homeostasis in
males, as impaired activation of this complex can reduce glucose
tolerance to a greater degree in male mice (Lamming et al., 2012,
2014b). Alterations in the activity of both mTOR complexes have also
been observed in other mouse models of lifespan extension: Snell dwarf
and growth hormone receptor-deficient mice show lowered mTORC1
signaling and increased mTORC2 signaling, in both sexes, which is
consistent with the lifespan extension observed in both sexes in these
models (Dominick et al., 2014).
Given the potential roles of mTOR signaling in sex differences in aging
and metabolism, we examined the phosphorylation status of several
mTOR substrates in livers of fasted males and females that had been
treated with ACA and 17aE2 for 8 months (i.e., tested at 12 months of
age). S6 and 4EBP1 are substrates downstream of mTORC1. S6
phosphorylation did not significantly change with either ACA or 17aE2
(Fig. 3A). In contrast, and surprisingly, phosphorylation of 4EBP1 was
increased with ACA (P = 0.016 for ACA and P = 0.06 for 17aE2), and to
a similar degree in males and females (Fig. 3B). We also note here that
total 4EBP1 protein levels were reduced in females, but were unaffected
by drug treatment in males (Table S1).
In contrast to the effects for mTORC1, the change in phosphorylation
of mTORC2 substrate NDRG1 in response to either ACA or EST is sex
specific (Fig. 3C; Table 1), with males showing an increase in NDRG1
phosphorylation in response to both drugs and females showing no
change. A similar pattern is observed for pSGK1 in mice treated with
17aE2, also downstream of mTORC2, with males alone showing
significantly increased activation in response to 17aE2 (Fig. 3D). For
ACA, there is no significant interaction between sex and treatment
(Table 1), with ACA increasing SGK1 phosphorylation in both males and
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females (effect across both sexes: P = 0.006). We note that this result for
pSGK1 should be viewed cautiously, because the antibody used to detect
pSGK1 at S422 is polyclonal, and in cell lysates has been reported to
detect a rapamycin-sensitive phosphorylated protein of a similar molec-
ular weight (Garcia-Martinez & Alessi, 2008). ACA and 17aE2 also led to
decreased levels of total NDRG1 in liver in both sexes, and ACA also
reduced levels of total SGK1 in a sex-independent manner (Table S1).
Alterations in substrate phosphorylation downstream of
mTORC2
Akt is a major mTORC2 target involved in the regulatory responses to
insulin. mTORC2 phosphorylates Akt at residue S473 but does not
phosphorylate T308 (Kennedy & Lamming, 2016). Both ACA and 17aE2
increase Akt phosphorylation at S473 in males but do not affect T308
(Fig. 4A), consistent with elevated mTORC2 activity and enhanced
insulin signaling. There is a significant sex by treatment interaction for
mice treated with 17aE2 (Table 1), indicating that males and females
show different changes in pAKT473 in response to 17aE2, with females
showing no change with treatment. For ACA, the sex by treatment
interaction is nonsignificant, but the main effect of treatment is
significant (P = 0.015), indicating that both males and females show
an increase in pAKT473 in response to ACA (Fig. 4A).
FOXO1 plays an important role in glucose metabolism. mTORC2 and
the PI3K-Akt/SGK1 pathway negatively regulate FOXO1 activity.
mTORC2 activity leads to phosphorylation of FOXO1 at T24, which
Fig. 1 Alterations in metabolic hormones (A–D) and insulin sensitivity (E–G) in male and female mice treated with ACA or 17aE2. Hormone levels (A–D) were assessed in
plasma samples collected from 12-month-old mice (n = 7–12 per sex, per group). Insulin tolerance tests were conducted in 9-month-old mice (n = 8 per group per sex). F&G
show the same set of data, plotted to show effects of treatment on sex differences (G) or the overall impact of treatment within each sex (F). Statistics showing overall effects
represent the P-value for a treatment parameter in a two-way ANOVA that also included a parameter for sex. * represents P < 0.05; *** presents P < 0.005 from a Student’s
t-test.
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contributes to nuclear exclusion and inhibition of hepatic FOXO1 activity
(Lamming et al., 2014a). We examined T24 phosphorylation of FOXO1
in whole tissue lysates, and observed that T24 phosphorylation is
increased in males but not females treated with 17aE2 (Fig. 4B), with the
significant interaction term indicating that males and females show a
significantly different change in FOXO1 phosphorylation in response to
Table 1 Summary of metabolic traits showing a sex-specific response to ACA and/or 17aE2, and effects of gonadectomy on these responses. Bold values denote
significance at P < 0.05.
Effect of ACA Effect of 17aE2
Sex by treatment
interactions
Surgery by treatment
interactions ACA
Surgery by treatment
interactions 17aE2
ACA 17aE2 Castration Ovariectomy Castration Ovariectomy
Insulin sensitivity (change in
glucose)
Decreased in females
(P = 0.02)
Increased in males
(P = 0.06)
P = 0.036 P = 0.030 Not tested Not tested Not tested Not tested
Glucose tolerance (AUC) Increased in males Increased in males P = 0.033 P = 0.003 P = 0.14 P = 0.84 P = 0.020 P = 0.35
Liver pNDRG1 Increased in males Increased in males P = 0.005 P = 0.034 P = 0.016 P = 0.044 P = 0.056 P = 0.049
Liver pSGK1 Increased Increased in males P = 0.34 P = 0.001 P = 0.18 P = 0.17 P = 0.003 P = 0.055
Liver pAKT473 Increased Increased in males P = 0.49 P = 0.026 P = 0.69 P = 0.48 P = 0.065 P = 0.37
Liver pFOXO1 Increased Increased in males P = 0.19 P = 0.002 P = 0.24 P = 0.20 P = 0.003 P = 0.072
Fig. 2 Enhanced glucose tolerance in males treated with ACA or 17aE2. Glucose tolerance tests were conducted in mice at either 9 or 22 months of age (n = 8–12 for each
sex in each treatment group at each test point); see methods for details. Bar graphs on right show the area under the curve calculated by using glucose levels at T = 0 as a
baseline, with P-values presenting the drug effect in a two-way ANOVA, including age as the second parameter, for each sex separately.
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treatment (Table 1). For ACA, there is no significant effect on FOXO1
phosphorylation, and there is no interaction between sex and treatment.
Sex hormones underlying sex-specific drug responses
Both testosterone and estrogens have been linked to sex differences in
lifespan (Maklakov & Lummaa, 2013; Regan & Partridge, 2013; Austad &
Bartke, 2015), and each of these hormones can influence glucose
tolerance and insulin sensitivity (Geer & Shen, 2009; Legato, 2010). To
test whether sex-specific responses to ACA and 17aE2 were dependent
on differences between males and females in adult life gonadal hormone
production, we castrated males and ovariectomized females at
3 months of age, then treated them with ACA or 17aE2 from 4 months
of age, that is, over the same time period as the sham-operated animals
presented above. Sham-operated mice and those subjected to gonadec-
tomy were produced, aged, and treated in parallel.
In contrast to intact males, castrated males showed no significant
improvement in their ability to clear glucose after ACAor 17aE2 treatment
when tested at 22 months of age (Fig. 5). For glucose levels relative to
baseline at each time point, we conducted two-factor ANOVAs and tested
Fig. 3 Activation of mTOR substrates in livers of mice treated with 17aE2. From liver samples taken at 12 months of age (n = 6 per group per sex). Statistics showing overall
effects (B) represent the P-value for a treatment parameter in a two-way ANOVA that also included a parameter for sex. * represents P < 0.05; ** represents P < 0.01; ***
represents P < 0.005 from a Student’s t-test conducted on the data separately from each sex.
Fig. 4 Sex-specific regulation of AKT473 and FOXO1 phosphorylation with ACA and 17aE2. From liver samples taken at 12 months of age (n = 6 per group per sex). **
represents P < 0.01 from a Student’s t-test conducted on the data separately from each sex.
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whether there was an interaction between treatment (e.g., control or
17aE2/ACA) and surgical status (gonadectomized or intact) within each
sex. A significant interaction term in such an analysis would demonstrate
an effect of castration on the treatment response in male mice. The effect
of 17aE2 on male glucose clearance is significantly altered by male
castration, both at the 30- and at 60-min time points (surgery*treatment
interaction: 30 min: P = 0.019; 60 min: P = 0.019), showing that the
male-specific benefit in termsof improvedglucose excursionwith this drug
is inhibited in castrated males. The effect of ACA on male glucose
clearance is also significantly altered bymale castration at the 60-min time
point (surgery*treatment interaction: P = 0.039), again showing that
castration significantly diminishes male treatment responses. Sham-
operated females did not show an improvement in glucose tolerance
with either drug treatment, and OVXmice were no different in this regard
(Fig. 5).
Reversal of mTORC2 signaling with castration and
ovariectomy
Tounderstandwhether sex-specific changes in hepaticmTORC2 signaling,
AKT and Foxo1 phosphorylation with drug treatment were also reversed
by gonadectomy, we evaluated phosphorylation of these substrates in
castratedmale and ovariectomized female mice that had been exposed to
ACA or 17aE2. Sex-specific activation of each of these substrates with
17aE2 ismodulatedby gonadectomy, and there is evidence that bothmale
castration and female ovariectomy can influence treatment responses.
Indeed, in a three-way ANOVA, including sex (male or female), treatment
(control or 17aE2), and surgery (gonads removed or sham surgery), for
each substrate, there is a significant sex*treatment*surgery interaction
highlighting the effect of gonadal hormones in modulating sex-specific
treatment responses in the liver (P = 0.05 for pAKT 473; P = 0.007 for
Fig. 5 No improvement in glucose tolerance in castrated males treated with ACA or 17aE2. Glucose tolerance tests were conducted in mice at 22 months of age (n = 8–12
for each sex in each treatment group at each test point). Data from intact animals are replicated from Fig. 2 and included here for ease of comparison. See methods for
details on GTT. Bar graphs on right show the area under the curve, with P-values above bars representing the effects of drug treatment for either castrated or intact males,
using a Student’s t-test.
Sex differences in lifespan–extension, M. Garratt et al. 1261
ª 2017 The Authors. Aging Cell published by the Anatomical Society and John Wiley & Sons Ltd.
pNDRG1; P = 0.001 for pFOXO1; P = 0.002 for pSGK1). The increase in
phosphorylation of these substrates that was seen in intact males with
17aE2 is not observed in castrated males (Fig. 6), revealing that male
gonadal hormones are required for male-specific treatment responses,
and there is a significant surgery by treatment interaction within males for
pSGK1 and pFOXO1 (Table 1). There is also some evidence that female
ovariectomy can modulate the female response to 17aE2, as there is a
significant surgery by treatment interaction within females for pNDRG1
(Fig. 6).
For ACA, we observed sex-specific phosphorylation only of NDRG1,
with the other substrates responding similarly in both sexes. For this
substrate, we also found a significant sex*treatment*surgery interaction
(P = 0.002), with two-way ANOVAs within each sex indicating that both
male castration and female ovariectomy influence treatment responses
(Table 1). Ovariectomized females show a significant increase in
phosphorylation of NDRG1 with ACA treatment (Fig. 6A), similar to
intact males, while castrated males show no change with treatment,
thus similar to the lack of response seen in intact females.
Discussion
Our results show that ACA and 17aE2, which lead to mouse lifespan
extension principally in males, also produce male-specific improvements
in glucose tolerance and elevations in hepatic mTORC2 activity. Females,
which do not show lifespan extension with 17aE2, and show only a 5%
improvement in median lifespan with ACA, do not show improved
glucose tolerance when treated with either drug, and show less
activation of mTORC2 substrates with treatment, particularly for
17aE2, consistent with the lack of any survival effect for 17aE2 in
female mice.
The data on sex-specific changes in mTORC2 signaling and glucose
tolerance are consistent with the recent observation that genetic
inhibition of mTORC2, either globally or specifically in the liver, reduces
lifespan specifically in males, without affecting females (Lamming et al.,
2014b). Both increases and decreases in male mouse lifespan, therefore,
seem to be linked to alterations in hepatic mTORC2 function, such that
increased mTORC2 activity is associated with male lifespan extension,
Fig. 6 Sex-specific regulation of mTORC2 substrates is mediated by gonadal hormones. Data from intact individuals are replicated from Figs 1 and 3, and shown here for
ease of comparison. Results from samples collected from 12-month-old mice, n = 6 per group. P-values were calculated using a Student’s t-test; see Table 1 for additional
details. * represents P < 0.05; ** represents P < 0.01; *** represents P < 0.005.
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while inhibiting mTORC2 activity reduces male survival. Activation of
mTORC2 is involved in the regulation of glucose uptake in response to
insulin (Kennedy & Lamming, 2016). Elevated mTORC2 activity may
promote hepatic responsiveness to insulin and could contribute to the
enhanced glucose tolerance with drug treatment observed in this sex. If
male lifespan is more sensitive to transient or postprandial perturbations
in glucose homeostasis than that of females, this sex specificity could
contribute to the differences in longevity effects. Alternatively, this
apparent relationship between male lifespan and mTORC2 signaling
could be related to some other function or regulator of mTORC2,
including lipids, leptin, or altered activity of TSC2. Understanding the
causal factors underlying this relationship, and the impact of mTOR
signaling in control of sex-specific metabolism and pathology in other
tissues types under periods of both feeding and fasting, may provide a
significant insight into the molecular signals controlling sexual dimor-
phism in aging.
The pathways through which 17aE2 improves male glucose tolerance
remain to be defined. 17aE2 binds only weakly to classical estrogen
receptors (Perez et al., 2005), although it can still elicit some
uterotrophic effects in OVX females (Strong et al., 2016). Some of the
metabolic effects of ERa activation also occur through protein–protein
interactions that are independent of nuclear translocation of the E2–ER
complex (Gupte et al., 2015). The activation of these responses requires
a much lower binding affinity of estrogens to ERa (Madak-Erdogan
et al., 2016) and thus could conceivably occur in response to 17aE2.
17aE2 crosses the blood–brain barrier and can have neuroprotective
effects in mouse models of ischemia (Perez et al., 2005), and 17aE2 can
bind to a brain-specific estrogen receptor ER-X (Toran-Allerand et al.,
2002, 2005). It was recently shown that both ACA and 17aE2 reduce
age-dependent hypothalamic inflammation in mice and that these
effects are much stronger in males (Sadagurski et al., 2017). Regulation
of glucose homeostasis and tissue-specific insulin signaling in drug-
treated mice might therefore involve CNS regulation of energy
metabolism, as reduced hypothalamic inflammation can improve
metabolic dysfunction (Cai & Liu, 2011) and even increase lifespan in
mice (Zhang et al., 2013).
Our results further reveal that sexually dimorphic responses to these
drugs are influenced by both male and female gonadal hormones, and
typically in opposite directions. Castrated males do not show improve-
ments in glucose tolerance with either ACA or 17aE2 and do not show
increased activity of hepatic mTORC2. Thus, male gonads, probably via
testosterone production, contribute to these sexually dimorphic meta-
bolic responses, with castrated males showing the lack of drug response
typical of intact females. Strikingly, OVX causes females to show some
phenotypic responses to treatment that are observed in intact males, but
not in intact females. Follow-up studies in which testosterone or 17-b
estradiol are administered throughout adult life to intact or gonadec-
tomized mice would be technically quite difficult. These would require
repeated injections, which can themselves potentially lead to effects on
health and hormone status, and would require duplication of age-related
changes in hormone levels, which would not be able to replicate
circadian and environmental influences in hormone levels. It may be
more feasible to explore these issues using mice with mutations in
receptors for androgens and estrogens, either globally or in specific cell
types. Nonetheless, these results suggest that both male and female
gonadal hormones contribute to sex differences in metabolic function
and intracellular signalling in response to ACA and 17aE2. It would be of
considerable interest to evaluate lifespan effects of both drugs in
castrated males and OVX females, and the development of other aspects
of age-associated metabolic dysfunction and pathology that are
differentially affected by treatment in each sex (e.g., Harrison et al.,
2014). Our work suggests that castrated males would show little or no
lifespan benefit from either drug and that OVX might allow females to
benefit from one or both of these interventions. Such data would be of
particular use as a guide toward developing drugs, in these classes, that
might slow aging or have other health benefits in both men and women.
The consistent effect of castration in inhibiting male responses to
drug treatment could occur via various postulated processes. Testos-
terone, or a protein/phenotype expressed in response to testosterone,
might alter bioactivity, conversion to bioactive forms, or cellular
responsiveness to either drug. For example, many genes involved in
xenobiotic metabolism show sexually dimorphic expression and are
partially controlled by the continuous production of sex hormones in
adult life (Waxman & Holloway, 2009). For ACA, however, the location
of drug action is thought to be in the small intestine, where ACA inhibits
alpha glucosidase, slowing the breakdown of complex carbohydrates to
absorbable glucose. This primary effect of ACA appears to occur in a sex-
independent manner, because fasting glucose levels are elevated to a
similar degree in both sexes. Thus, sex- and hormone-dependent
differences in ACA responses presumably reflect consequences of
alterations in responses to transient postprandial glucose excursions,
rather than to the direct effects of ACA itself on glucosidase function.
The lack of drug effects on castrated males, and the facilitation of
drug effects by OVX in females, may reflect opposing effects of sex
hormones on aspects of physiology linked to lifespan. Male castration
extends male lifespan in various species (Brooks & Garratt, 2017),
including situations in which castration is delayed until after puberty
(Asdell et al., 1967; Drori & Folman, 1976), while OVX has been
reported to reduce female mouse survival when conducted in adulthood
(Benedusi et al., 2015). Our work shows that at least some of the sex-
specific effects of ACA and 17aE2 reflect actions of gonadal hormones in
adult, that is, postpubertal mice, and do not reflect sexual dimorphisms
established prior to 3 months of age. Adult castration and OVX have
also been reported to have opposing effects on specific cell responses to
insulin, at least in mouse adipocytes, which become more insulin
sensitive in castrated male mice, while OVX has the opposite effect in
females (Macotela et al., 2009). However, the observation that lifespan
of males treated with 17aE2 exceeds that of both control- and 17aE2-
treated females (Strong et al., 2016), suggests that this treatment does
not simply protect against some male dysfunction that reduces male
lifespan in relation to that of normal females.
Our work does not establish whether the beneficial antiaging effects
of ACA and 17aE2 require improved glucose handling and/or altered
responses to insulin, in the liver, or in any other cell type. Comparison of
glucose tolerance in mice tested at 9 or 22 months of age suggested
that the older mice might have more effective glucose clearance, but
this inference must be taken with great caution, because the two
groups were tested approximately one year apart, making direct
comparisons hazardous. Nonetheless, ACA and 17aE2 do not appear
to specifically protect against age-associated declines in glucose
tolerance, as observed in some lifespan models in C57BL/6 mice (Bl€uher
et al., 2002; Selman et al., 2008), where glucose levels in older animals
remain consistently high following an administered glucose bolus.
Rather, we find that ACA and 17aE2 produce male-specific improve-
ments in glucose tolerance consistent across most of adult life. How
such changes in glucose tolerance and underlying insulin signaling might
be linked to improved male survival requires further investigation. It is
also notable that although ACA-treated females appear to show a slight
reduction in glucose tolerance and insulin sensitivity compared to
untreated female controls, this sex still shows a significant, albeit
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smaller, lifespan extension in response to ACA. At least part of the
lifespan-extension effect in ACA-treated females is therefore indepen-
dent of improved glucose tolerance, although hepatic phosphorylation
of SGK1 and AKT was increased in both sexes, which might promote
insulin signaling specifically at this site. We observe that both plasma
IGF1 and adiponectin concentrations are reduced with ACA treatment,
in a sex-independent manner, showing that additional/complementary
endocrine pathways are modulated by ACA. The reduction in plasma
adiponectin contrasts with effects observed in other mouse lifespan-
extension models, including GHR-knockout (Berryman et al., 2004) and
DR-treated mice (Cawthorn et al., 2014), which show increased
circulating adiponectin. In this study, we assessed total plasma
adiponectin, but it has recently been shown that changes specifically
in the high molecular weight isoform of adiponectin can occur with DR
(Miller et al., 2017), and this isoform may provide specific metabolic
benefits. Reduced circulating IGF1 is a potential candidate linking to
ACA to increased female lifespan, as reduced IGF1 signaling can extend
mouse lifespan, with preferential survival benefits in females (Garratt
et al., 2017). Greater understanding of the physiological and underlying
hormonal causes for sexual dimorphism in lifespan extension with ACA
and 17aE2, and for that matter reduced mTOR signaling and IGF1
signaling (which preferentially extend female lifespan), could provide
significant insights into sexual dimorphism in the aging process and
provide guidance to the development of drugs that are confer health
benefits in one or both sexes.
Experimental procedures
UM-HET3 mice were produced as previously described (e.g., Miller et al.,
2014; Strong et al., 2016). The mothers of the test mice were CByB6F1/
J, JAX stock #100009, whose female parents are BALB/cByJ and whose
male parents are C57BL/6J. The fathers of the test mice were C3D2F1/J,
JAX stock #100004, whose mothers are C3H/HeJ and whose fathers are
DBA/2J. Mice in breeding cages received Purina 5008 mouse chow, and
weaned animals were fed Purina 5LG6.
Mice were housed as previously described (e.g., Miller et al., 2014;
Strong et al., 2016) in plastic cages with metal tops, using ¼-inch corn-
cob bedding (Bed O’Cobs, produced by The Andersons, PO Box 114,
Maumee, OH, USA). Mice were given free access to water, using water
bottles rather than an automated watering system. Mice were housed in
ventilated cages and were transferred to fresh cages every 14 days.
Temperature was maintained within the range of 21–23°C.
Surgical procedures
At 3 months of age, all animals went through castration, ovariectomy,
or a sham procedure. All animals were anesthetized by injection of
250 mg kg1 tribromoethanol, and given a single preoperative injection
of the analgesia carprofen, at 5 mg kg1.
Castration and sham castration
After surgical preparation, an incision was made in the caudal end of
each scrotal sac, the testicle was pulled through the incision by gentle
traction, and the blood vessels, vas deferens, and deferential vessels
were clamped and sutured. The incision was closed with tissue adhesive.
For sham surgery, the testicles were exteriorized and then replaced in the
scrotum, without being ligated or excised.
Ovariectomy or sham ovariectomy
After surgical preparation, an incision was made on the left side
perpendicular to the vertebral column approximately midway between
the iliac crest and the last rib. The ovarian fat pad was grasped and
exteriorized. The pedicle under the ovarian blood vessels and fat pad
under the ovary were grasped and crushed, the pedicle cut on the ovary
side and the ovary removed, and the blood vessels tied with absorbable
suture. The abdominal wall was closed with absorbable suture and skin
was closed with staples. The procedure was then repeated on the
opposite side. For sham ovariectomy, animals underwent the same
surgical procedure, but the ovary and fat pad were exteriorized and
replaced without being excised.
Diets
At 4 months of age, animals in different sibling groups were
randomly allocated to control, ACA, or 17aE2 treatment. Animals in
the control group remained on the 5LG6 diet, while animals allowed
allocated to ACA or 17aE2 had their diet switched to one of these
experimental diets.
All diets were prepared by TestDiet, Inc., a division of Purina Mills
(Richmond, IN, USA). Purina 5LG6 food contained each of the test
substances and was used as the control diet. 17aE2 was purchased from
Steraloids Inc. (Newport, RI, USA) and mixed at a dose of 14.4 milligrams
per kilogram diet (14.4 ppm). Acarbose was purchased from Spectrum
Chemical Mfg. Corp., Gardena, CA, USA, and was mixed at a
concentration of 1000 mg of ACA per kilogram of diet (1000 ppm).
These methods followed those used by the NIA Interventions Testing
Program.
Metabolic analysis
Intraperitoneal glucose tolerance tests were performed on mice fasted
for 16 h overnight. Blood glucose levels were measured using a
Glucometer Elite (Bayer), after which mice were injected intraperitoneally
(ip) with D-glucose (2 g kg1), and blood glucose levels were monitored
over 120 min. For insulin tolerance tests, mice were fasted for a four-
hour period in the light cycle before ip injections of insulin (0.8 U kg1;
Humulin R) diluted in sterile saline. Blood glucose concentrations were
measured at the indicated time points.
Blood insulin, leptin, and total adiponectin levels were determined in
plasma collected after an 18 hour fast using ELISA kits from Crystal
Chem (Downers Grove, IL, USA). Blood IGF1 levels were assessed in
plasma using the Mouse/Rat ELISA kit from ALPCO (Boston, MA, USA).
Hepatic mTOR signaling
Livers were harvested during the morning, from 12-month-old mice after
18 h of fasting. Tissues were frozen with liquid nitrogen and stored at
80°C. Tissues were processed, whole-cell lysates were obtained, and
equal amounts of protein were loaded for Western blot analysis.
Antibodies and phospho-specific rabbit antibodies were purchased from
Cell Signaling (pAKT 308: 9275; pAKT 473: 4060; total AKT: 9272; total
FOXO1: 2880; pFOXO1 T24: 9464; total S6: 2217; pS6: 2211; p4EBP1:
2855; total 4EBP1: 9644; total NDRG1: 9408; pNDRG1: 5482 – www.ce
llsignal.com), Santa Cruz (pSGK1: 16745 – www.scbt.com), and
Genetex (SGK1: 61249 – http://www.genetex.com).
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Statistics
Statistics were carried out in SPSS version 22. Data from animals treated
with ACA and 17aE2 were analyzed separately, but the same control
animals were used in both sets of analysis. For each measured parameter,
we conducted a two-factor ANOVA, using the general linear model
function and a full factorial model, which included an effect of treatment
(comparing control to either ACA or 17aE2), an effect of sex (male or
female), and an interaction between sex and treatment. When testing for
the effect of gonadectomy on treatment responses within each sex, we
included an effect of treatment, an effect of surgery (gonadectomized or
not), and an interaction between surgery and treatment. For those
parameters that suggested there couldbeaneffect of bothmale castration
and female ovariectomy (P < 0.1 for the two-way interaction term) on sex-
specific treatment responses, we conducted three-way ANOVAs across
data from both males and females of both surgical status, including fixed
effects of sex, treatment, and surgical status, and interaction terms
between each. Data were transformed where necessary to conform to
assumptions of normality.
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